Should I buy or sell Dynavax Technologies stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dynavax Technologies in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" DVAX shares. View DVAX analyst ratings or view top-rated stocks .

What is Dynavax Technologies' stock price target for 2024?

4 brokers have issued 1-year target prices for Dynavax Technologies' shares. Their DVAX share price targets range from $20.00 to $28.00. On average, they anticipate the company's stock price to reach $25.00 in the next year. This suggests a possible upside of 118.7% from the stock's current price. View analysts price targets for DVAX or view top-rated stocks among Wall Street analysts .

How have DVAX shares performed in 2024?

Dynavax Technologies' stock was trading at $13.98 on January 1st, 2024. Since then, DVAX stock has decreased by 18.2% and is now trading at $11.43. View the best growth stocks for 2024 here .

When is Dynavax Technologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024. View our DVAX earnings forecast .

How were Dynavax Technologies' earnings last quarter?

Dynavax Technologies Co. (NASDAQ:DVAX) announced its earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.05 by $0.29. The biopharmaceutical company earned $108.27 million during the quarter, compared to the consensus estimate of $77.30 million. Dynavax Technologies had a negative net margin of 2.75% and a negative trailing twelve-month return on equity of 1.08%. During the same quarter in the prior year, the firm earned ($0.15) EPS.

What ETFs hold Dynavax Technologies' stock?

ETFs with the largest weight of Dynavax Technologies (NASDAQ:DVAX) stock in their portfolio include Amplify Treatments, Testing and Advancements ETF (GERM) , Invesco Biotechnology & Genome ETF (PBE) , Invesco S&P SmallCap Health Care ETF (PSCH) , Franklin Genomic Advancements ETF (HELX) , SPDR S&P Biotech ETF (XBI) , Direxion Daily S&P Biotech Bull 3x Shares (LABU) and First Trust Small Cap Growth AlphaDEX Fund (FYC) . WisdomTree U.S. SmallCap Fund (EES) .

What is Eddie Gray's approval rating as Dynavax Technologies' CEO?

13 employees have rated Dynavax Technologies Chief Executive Officer Eddie Gray on Glassdoor.com . Eddie Gray has an approval rating of 59% among the company's employees. This puts Eddie Gray in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 61.0% of employees surveyed would recommend working at Dynavax Technologies to a friend.

What other stocks do shareholders of Dynavax Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dynavax Technologies investors own include Puma Biotechnology (PBYI) , BioMarin Pharmaceutical (bmrn) , (MDVN) (MDVN) , Incyte (incy) , Sorrento Therapeutics (SRNE) , Vaxart (VXRT) , Matinas BioPharma (MTNB) , First Solar (FSLR) , Inovio Pharmaceuticals (INO) and ADMA Biologics (ADMA) .

Who are Dynavax Technologies' major shareholders?

Dynavax Technologies' stock is owned by many different institutional and retail investors. Top institutional shareholders include Congress Asset Management Co. MA (0.18%). Insiders that own company stock include Andrew A F Hack , David F Novack, David F Novack , Francis Cano, Justin Burgess , Robert Janssen and Ryan Spencer . View institutional ownership trends .

How do I buy shares of Dynavax Technologies?

Shares of DVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:DVAX

Dynavax Technologies (DVAX) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free DVAX Stock Alerts

$11.43

-0.06 (-0.52%)

(As of 04/17/2024 ET)

Compare

Today's Range: $11.34
▼
$11.56
50-Day Range: $11.49
▼
$13.14
52-Week Range: $10.06
▼
$15.15

Volume: 2.55 million shs
Average Volume: 1.94 million shs
Market Capitalization: $1.50 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $25.00

Get Dynavax Technologies alerts:

Dynavax Technologies MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.75 Rating Score
Upside/Downside: 118.7% Upside
$25.00 Price Target
Short Interest: Bearish
13.73% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.59
Upright™ Environmental Score
News Sentiment: 1.67
Based on 2 Articles This Week
Insider Trading: Selling Shares
$262,322 Sold Last Quarter
Proj. Earnings Growth: 79.17%
From $0.24 to $0.43 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.44 out of 5 stars

Medical Sector

93rd out of 913 stocks

Pharmaceutical Preparations Industry

26th out of 398 stocks

3.4

Analyst's Opinion

Consensus Rating
Dynavax Technologies has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Dynavax Technologies has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
13.73% of the outstanding shares of Dynavax Technologies have been sold short.
Short Interest Ratio / Days to Cover
Dynavax Technologies has a short interest ratio ("days to cover") of 9.2.
Change versus previous month
Short interest in Dynavax Technologies has recently increased by 3.57%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Dynavax Technologies does not currently pay a dividend.
Dividend Growth
Dynavax Technologies does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Dynavax Technologies has received a 74.16% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Hepatitis B vaccines", "Clinical research services for infectious diseases", and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Dynavax Technologies is -1.59.

3.7

News and Social Media Coverage

News Sentiment
Dynavax Technologies has a news sentiment score of 1.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Dynavax Technologies this week, compared to 3 articles on an average week.
Search Interest
8 people have searched for DVAX on MarketBeat in the last 30 days. This is an increase of 14% compared to the previous 30 days.
MarketBeat Follows
6 people have added Dynavax Technologies to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Dynavax Technologies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $262,322.00 in company stock.
Percentage Held by Insiders
Only 9.31% of the stock of Dynavax Technologies is held by insiders.
Percentage Held by Institutions
96.96% of the stock of Dynavax Technologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Dynavax Technologies are expected to grow by 79.17% in the coming year, from $0.24 to $0.43 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Dynavax Technologies is -190.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Dynavax Technologies is -190.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Dynavax Technologies has a P/B Ratio of 2.38. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Dynavax Technologies Stock (NASDAQ:DVAX)

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.

DVAX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

DVAX Stock News Headlines

April 9, 2024 | stocknews.com

3 Biotech Buys Under $15

March 25, 2024 | finance.yahoo.com

Those who invested in Dynavax Technologies (NASDAQ:DVAX) five years ago are up 68%

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 24, 2024 | seekingalpha.com

Dynavax Technologies: Still A Believer

March 24, 2024 | seekingalpha.com

Dynavax Technologies: Still A Believer

March 23, 2024 | seekingalpha.com

Dynavax: Holding Firm Despite Its Missing Cash Cow

March 23, 2024 | seekingalpha.com

Dynavax: Holding Firm Despite Its Missing Cash Cow

March 15, 2024 | bizjournals.com

How vaccine maker Dynavax tested itself and found a corporate cure

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 14, 2024 | forbes.com

Dynavax CFO Kelly MacDonald: Making An Impact In The Biotech Industry

March 10, 2024 | uk.finance.yahoo.com

Dynavax Technologies Corporation (DVAX)

March 5, 2024 | finance.yahoo.com

Chief Accounting Officer Justin Burgess Sells Shares of Dynavax Technologies Corp (DVAX)

February 27, 2024 | finance.yahoo.com

Dynavax Technologies Corp (DYF1.DU)

February 27, 2024 | prnewswire.com

Dynavax to Present at TD Cowen's 44th Annual Health Care Conference

February 24, 2024 | msn.com

Dynavax GAAP EPS of $0.00 beats by $0.01, revenue of $55.6M beats by $2.87M

February 24, 2024 | markets.businessinsider.com

Dynavax’s Strong Financials and Promising Pipeline Secure Buy Rating

February 23, 2024 | markets.businessinsider.com

Dynavax’s Strong Financial Outlook and Heplisav-B Market Expansion Prompt ‘Buy’ Rating

February 23, 2024 | finance.yahoo.com

Dynavax Technologies Corporation (NASDAQ:DVAX) Q4 2023 Earnings Call Transcript

February 23, 2024 | finanznachrichten.de

Dynavax Technologies: Dynavax Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Financial Guidance

February 22, 2024 | benzinga.com

Dynavax Technologies: Q4 Earnings Insights

February 22, 2024 | finance.yahoo.com

Dynavax Technologies Corp (DVAX) Reports Robust Revenue Growth and Market Leadership in 2023

February 22, 2024 | fool.com

Dynavax Technologies (DVAX) Q4 2023 Earnings Call Transcript

February 22, 2024 | seekingalpha.com

Dynavax Technologies Corporation 2023 Q4 - Results - Earnings Call Presentation

February 22, 2024 | prnewswire.com

Dynavax Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Financial Guidance

February 22, 2024 | markets.businessinsider.com

Here's what Wall Street expects from Dynavax Technologies's earnings

February 22, 2024 | msn.com

Dynavax Q4 2023 Earnings Preview

February 18, 2024 | finance.yahoo.com

DVAX Jul 2024 18.000 call

See More Headlines

Receive DVAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dynavax Technologies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/04/2021
Today: 4/17/2024
Next Earnings (Estimated): 5/07/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Current Symbol: NASDAQ:DVAX
CUSIP: 26815810
CIK: 1029142
Web: www.dynavax.com
Phone: (510) 848-5100
Fax: 510-848-1327
Employees: 408
Year Founded: 1996

Price Target and Rating

Average Stock Price Target: $25.00
High Stock Price Target: $28.00
Low Stock Price Target: $20.00
Potential Upside/Downside: +118.7%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.75
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.06)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 47.63
P/E Growth: N/A
Net Income: $-6,390,000.00
Net Margins: -2.75%
Pretax Margin: -1.88%
Return on Equity: -1.08%
Return on Assets: -0.66%

Debt

Debt-to-Equity Ratio: 0.41
Current Ratio: 13.81
Quick Ratio: 12.96

Sales & Book Value

Annual Sales: $232.28 million
Price / Sales: 6.44
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.81 per share
Price / Book: 2.38

Miscellaneous

Outstanding Shares: 130,860,000
Free Float: 118,680,000
Market Cap: $1.50 billion
Optionable: Optionable
Beta: 1.26

Social Links

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Mr. Ryan Spencer (Age 46)
CEO & Director
Comp: $1.25M
Mr. David F. Novack (Age 62)
President & COO
Comp: $925.6k
Ms. Kelly MacDonald (Age 40)
Senior VP & CFO
Comp: $674.27k
Dr. Robert Janssen (Age 70)
Chief Medical Officer and Senior VP of Clinical Development, Medical & Regulatory Affairs
Comp: $789.76k
Mr. Justin Burgess
Principal Accounting Officer & Controller
Mr. Jeff P. Coon (Age 61)
CHRO and Senior VP of Human Resources & Administration
Mr. Paul Cox
VP of Investor Relations & Corporate Communications
Mr. John Slebir
Senior VP & General Counsel
Mr. Donn Casale
Chief Commercial Officer
Dr. Dong Yu
Senior Vice President of Vaccine Research

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

DVAX Stock Analysis - Frequently Asked Questions

Should I buy or sell Dynavax Technologies stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dynavax Technologies in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" DVAX shares.
View DVAX analyst ratings or view top-rated stocks.
What is Dynavax Technologies' stock price target for 2024?: 4 brokers have issued 1-year target prices for Dynavax Technologies' shares. Their DVAX share price targets range from $20.00 to $28.00. On average, they anticipate the company's stock price to reach $25.00 in the next year. This suggests a possible upside of 118.7% from the stock's current price.
View analysts price targets for DVAX or view top-rated stocks among Wall Street analysts.
How have DVAX shares performed in 2024?: Dynavax Technologies' stock was trading at $13.98 on January 1st, 2024. Since then, DVAX stock has decreased by 18.2% and is now trading at $11.43.
View the best growth stocks for 2024 here.
When is Dynavax Technologies' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024.
View our DVAX earnings forecast.
How were Dynavax Technologies' earnings last quarter?: Dynavax Technologies Co. (NASDAQ:DVAX) announced its earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.05 by $0.29. The biopharmaceutical company earned $108.27 million during the quarter, compared to the consensus estimate of $77.30 million. Dynavax Technologies had a negative net margin of 2.75% and a negative trailing twelve-month return on equity of 1.08%. During the same quarter in the prior year, the firm earned ($0.15) EPS.
What ETFs hold Dynavax Technologies' stock?: ETFs with the largest weight of Dynavax Technologies (NASDAQ:DVAX) stock in their portfolio include Amplify Treatments, Testing and Advancements ETF (GERM), Invesco Biotechnology & Genome ETF (PBE), Invesco S&P SmallCap Health Care ETF (PSCH), Franklin Genomic Advancements ETF (HELX), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and First Trust Small Cap Growth AlphaDEX Fund (FYC).WisdomTree U.S. SmallCap Fund (EES).

What is Eddie Gray's approval rating as Dynavax Technologies' CEO?: 13 employees have rated Dynavax Technologies Chief Executive Officer Eddie Gray on Glassdoor.com. Eddie Gray has an approval rating of 59% among the company's employees. This puts Eddie Gray in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 61.0% of employees surveyed would recommend working at Dynavax Technologies to a friend.
What other stocks do shareholders of Dynavax Technologies own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Dynavax Technologies investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (bmrn), (MDVN) (MDVN), Incyte (incy), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Matinas BioPharma (MTNB), First Solar (FSLR), Inovio Pharmaceuticals (INO) and ADMA Biologics (ADMA).
Who are Dynavax Technologies' major shareholders?: Dynavax Technologies' stock is owned by many different institutional and retail investors. Top institutional shareholders include Congress Asset Management Co. MA (0.18%). Insiders that own company stock include Andrew A F Hack, David F Novack, David F Novack, Francis Cano, Justin Burgess, Robert Janssen and Ryan Spencer.
View institutional ownership trends.
How do I buy shares of Dynavax Technologies?: Shares of DVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:DVAX) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Dynavax Technologies (DVAX) Stock Price, News & Analysis

Dynavax Technologies MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Dynavax Technologies Stock (NASDAQ:DVAX)

DVAX Stock Price History

DVAX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

DVAX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™